360 related articles for article (PubMed ID: 32259417)
61. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
62. Polo-like kinase 1 is essential for the first mitotic division in the mouse embryo.
Baran V; Solc P; Kovarikova V; Rehak P; Sutovsky P
Mol Reprod Dev; 2013 Jul; 80(7):522-34. PubMed ID: 23649868
[TBL] [Abstract][Full Text] [Related]
63. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.
Degenhardt Y; Greshock J; Laquerre S; Gilmartin AG; Jing J; Richter M; Zhang X; Bleam M; Halsey W; Hughes A; Moy C; Liu-Sullivan N; Powers S; Bachman K; Jackson J; Weber B; Wooster R
Mol Cancer Ther; 2010 Jul; 9(7):2079-89. PubMed ID: 20571075
[TBL] [Abstract][Full Text] [Related]
64. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
65. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
[TBL] [Abstract][Full Text] [Related]
66. Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
Shin SB; Kim CH; Jang HR; Yim H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207738
[TBL] [Abstract][Full Text] [Related]
67. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
68. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
[TBL] [Abstract][Full Text] [Related]
70. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
71. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
[TBL] [Abstract][Full Text] [Related]
72. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
73. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
[TBL] [Abstract][Full Text] [Related]
74. Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.
Schmidt M; Hofmann HP; Sanders K; Sczakiel G; Beckers TL; Gekeler V
Mol Cancer Ther; 2006 Apr; 5(4):809-17. PubMed ID: 16648550
[TBL] [Abstract][Full Text] [Related]
75. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
76. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713
[TBL] [Abstract][Full Text] [Related]
77. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.
VanderWeele DJ; Zhou R; Rudin CM
Mol Cancer Ther; 2004 Dec; 3(12):1605-13. PubMed ID: 15634654
[TBL] [Abstract][Full Text] [Related]
78. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Wissing MD; Mendonca J; Kortenhorst MS; Kaelber NS; Gonzalez M; Kim E; Hammers H; van Diest PJ; Carducci MA; Kachhap SK
FASEB J; 2013 Oct; 27(10):4279-93. PubMed ID: 23884428
[TBL] [Abstract][Full Text] [Related]
79. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
80. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]